{
    "clinical_study": {
        "@rank": "137829", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: GDC-0032 + Docetaxel", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B: GDC-0032 + Paclitaxel", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, dose-escalation study designed to assess the safety,\n      tolerability, and pharmacokinetics of GDC-0032 administered in combinat ion with either\n      docetaxel (Arm A) or with paclitaxel (Arm B) in patients with HE R2-negative locally\n      recurrent or metastatic breast cancer. Stage 1: Both Arms A and B will employ a\n      dose-escalation design with escalating doses of GDC-0032.\n\n      Once the maximum tolerated dose of GDC-0032 has been established, additional pa tients will\n      be enrolled in the cohort-expansion stage (Stage 2)."
        }, 
        "brief_title": "A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adenocarcinoma of the breast with locally recurrent or metastatic disease\n\n          -  HER2-negative disease\n\n          -  Evaluable or measurable disease per RECIST v.1.1\n\n          -  Life expectancy >= 12 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening\n\n          -  Adequate hematologic and end organ function\n\n        Exclusion Criteria:\n\n          -  Known significant hypersensitivity to any components of study treatment\n\n          -  Grade >= 2 peripheral neuropathy\n\n          -  Grade >= 2 hypercholesterolemia or hypertriglyceridemia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862081", 
            "org_study_id": "GO27802"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: GDC-0032 + Docetaxel", 
                "description": "Stage 1: escalating doses of GDC-0032; Stage 2: maximum tolerated dose of GDC-0032", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: GDC-0032 + Paclitaxel", 
                "description": "Stage 1: escalating doses of GDC-0032; Stage 2: maximum tolerated dose of GDC-0032", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A: GDC-0032 + Docetaxel", 
                "description": "Docetaxel intravenously", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: GDC-0032 + Paclitaxel", 
                "description": "Paclitaxel intravenously", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33607"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02130"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12206"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yakima", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98902"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO27802 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of dose limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the curve from time 0 to the last measurable concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Time to maximum observed plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Maximum observed plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Minimum observed plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "measure": "Duration of response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }, 
            {
                "measure": "Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 years"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}